Answer
The press release does not spell out a numeric year‑over‑year (YoY) growth rate for the commercial‑revenue segment; it only notes that “second‑quarter 2025 revenue of over $400,000” reflects “commercial revenue growth.” Because the exact percentage change from Q2 2024 to Q2 2025 isn’t disclosed in the excerpt, the precise YoY growth rate cannot be calculated from the information provided.
Trading implications
- Fundamentals: The fact that RenovoRx generated > $400 k in commercial sales in Q2 2025—up from a much lower or possibly zero baseline a year earlier—signals a meaningful shift from a purely R&D‑focused model toward a revenue‑generating business. This transition can broaden the company’s cash‑flow profile and may reduce the discount applied to its valuation relative to pure‑play clinical‑stage peers.
- Technical outlook: The stock has likely already priced in the early‑stage commercial traction, but the lack of a concrete YoY growth figure leaves room for upside if the upcoming earnings call or the full SEC filing confirms a strong percentage increase (e.g., > 100 % YoY). A breakout above recent resistance (around the Q2‑2025 price level) on the confirmation of robust YoY growth could trigger short‑term buying pressure. Conversely, if the YoY growth is modest, the price may revert toward its prior support levels.
Actionable insight – Until the full earnings release or the 10‑Q filing reveals the exact YoY growth percentage, consider a cautious, position‑sizing approach: hold existing positions if you’re already long, but avoid adding new exposure until the quantitative growth metric is confirmed. If the disclosed YoY growth exceeds 100 %, a short‑term bullish play on the next price rally would be justified; if it’s below 50 %, a more defensive stance may be warranted.